This month has seen the publication of a manuscript reporting on the safety and clinical pharmacology of a novel oral liquid formulation of 13-cis retinoic acid in children with neuroblastoma. The study published in the journal Cancers (https://www.mdpi.com/2072-6694/13/8/1868), showed that the liquid formulation demonstrated superior bioavailability, increasing the likelihood of achieving therapeutic levels, and that safety and palatability also compared favourably to the capsule formulation. This new formulation is now available from Nova Laboratories.